Gain Therapeutics (GANX) Operating Leases (2020 - 2025)
Historic Operating Leases for Gain Therapeutics (GANX) over the last 6 years, with Q3 2025 value amounting to $65026.0.
- Gain Therapeutics' Operating Leases fell 3242.09% to $65026.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $65026.0, marking a year-over-year decrease of 3242.09%. This contributed to the annual value of $53598.0 for FY2024, which is 7668.18% down from last year.
- Per Gain Therapeutics' latest filing, its Operating Leases stood at $65026.0 for Q3 2025, which was down 3242.09% from $92851.0 recorded in Q2 2025.
- Gain Therapeutics' Operating Leases' 5-year high stood at $695053.0 during Q4 2021, with a 5-year trough of $30589.0 in Q1 2025.
- In the last 5 years, Gain Therapeutics' Operating Leases had a median value of $377598.0 in 2021 and averaged $338137.7.
- As far as peak fluctuations go, Gain Therapeutics' Operating Leases surged by 7362.26% in 2021, and later plummeted by 9199.1% in 2025.
- Gain Therapeutics' Operating Leases (Quarter) stood at $695053.0 in 2021, then crashed by 36.44% to $441784.0 in 2022, then crashed by 47.97% to $229855.0 in 2023, then tumbled by 76.68% to $53598.0 in 2024, then increased by 21.32% to $65026.0 in 2025.
- Its last three reported values are $65026.0 in Q3 2025, $92851.0 for Q2 2025, and $30589.0 during Q1 2025.